MEI Pharma (MEIP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MEIP MEI Pharma

Watchlist

2.7300
-0.0400-1.44%

Close Dec 4 16:00 ET

2.7300
0.00000.00%

Post 20:01 ET

18.19MMarket Cap-390P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

MEI Pharma Reports Strategic Shift Amid Financial Losses
TipRanksNov 13 23:14 ET
Press Release: MEI Acquires Dalrymple Rigging and Transport
Dow JonesNov 13 10:01 ET
MEI Pharma | 10-Q: Q1 2025 Earnings Report
SECNov 12 16:46 ET · Announcements
Press Release: MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Dow JonesNov 12 16:05 ET
MEI Pharma 1Q Loss $8.01M >MEIP
Dow JonesNov 12 16:05 ET
MEI Pharma Stock Jumps 8% on Sale of Drug Asset ME-344
Seeking AlphaOct 28 11:59 ET

Comments

Jaguar8

Oct 28 00:23

Watch tomorrow. 8K filed Friday. Biotech low float, sold assets, initial $500K up to $60M upon reaching certain milestones

$MEI Pharma (MEIP.US)$
“On October 22, 2024 (the “Closing Date”), MEI Pharma, Inc., a Delaware corporation (the “Company”), and Aardvark Therapeutics, Inc., a Delaware corporation (the “Purchaser”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which the Company sold its rights, title and interest in and to certain assets related to ME-...

Stock_Drift

Oct 25 15:54

After Hours Ticks. 4:52pm

$Pasithea Therapeutics (KTTA.US)$ $Gulf Resources (GURE.US)$ $Sadot (SDOT.US)$ $Edesa Biotech (EDSA.US)$ $Crown Electrokinetics (CRKN.US)$ $P3 Health Partners (PIII.US)$ $MIRA Pharmaceuticals (MIRA.US)$ $Sky Quarry (SKYQ.US)$ $FGI Industries (FGI.US)$ $Check-Cap (CHEK.US)$ $MEI Pharma (MEIP.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$

George Soros II

Oct 25 15:17

$MEI Pharma (MEIP.US)$
Wohooo

Jaguar8

Apr 11 07:05

$MEI Pharma (MEIP.US)$
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...